Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18102338 | 1.00 | TSHR (0.64) | TSHRPSMD14HSD11B1HPGDALDH1A1 | |
| SCHEMBL22380663 | 1.00 | TSHR (0.64) | TSHRPSMD14HSD11B1HPGDALDH1A1 | |
| SCHEMBL24443096 | 0.79 | TSHR (0.56) | TSHRPSMD14ALDH1A1KDM4EHTT | |
| SCHEMBL18410888 | 0.79 | TSHR (0.56) | TSHRPSMD14ALDH1A1KDM4EHTT | |
| SCHEMBL840077 | 0.77 | PSMD14 (0.44) | TSHRPSMD14HSD11B1HPGDALDH1A1 | |
| SCHEMBL22623766 | 0.77 | PSMD14 (0.44) | TSHRPSMD14HSD11B1HPGDALDH1A1 | |
| SCHEMBL3080998 | 0.77 | PSMD14 (0.77) | TSHRPSMD14HSD11B1HPGDALDH1A1 | |
| SCHEMBL20669715 | 0.77 | TSHR (0.46) | TSHRPSMD14HSD11B1 | |
| SCHEMBL14508243 | 0.77 | TSHR (0.46) | TSHRPSMD14HSD11B1 | |
| SCHEMBL24743766 | 0.74 | TSHR (0.51) | TSHRPSMD14KDM4EHTTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239823-A1 | PHOSPHINATE ESTER-CONTAINING DYES HAVING TUNABLE PROPERTIES AND METHODS OF MAKING THE SAME | NUTECH VENTURES | 2024-07-18 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240018108-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-18 | — | — | US | disclosed |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-7459473-B2 | N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres | GLIA MED, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-7265150-B1 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders | GPI NIL HOLDINGS INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253169-B2 | Aza compounds, pharmaceutical compositions and methods of use | GLIAMED, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239823-A1 | PHOSPHINATE ESTER-CONTAINING DYES HAVING TUNABLE PROPERTIES AND METHODS OF MAKING THE SAME | PPOX, PNPO, PHOSPHO1 | TSHR 1870/4885PSMD14 4729/4885HSD11B1 2692/4885 |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | OR51E2, OR10J3, ORC3 | TSHR 1036/4885PSMD14 1491/4885HSD11B1 3462/4885 |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | TSHR 2190/4885PSMD14 3376/4885HSD11B1 2/4885 |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | BCL6B, BCL6, BTD | TSHR 1895/4885PSMD14 4528/4885HSD11B1 2775/4885 |
| US-20240018108-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, FAH | TSHR 3289/4885PSMD14 3119/4885HSD11B1 884/4885 |
| US-20230381137-A1 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, CYP19A1 | TSHR 82/4885PSMD14 886/4885HSD11B1 473/4885 |
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | TSHR 2551/4885PSMD14 3449/4885HSD11B1 3189/4885 |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD3B1, HSD17B1, HSD3B2 | TSHR 1065/4885PSMD14 2232/4885HSD11B1 4/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | TSHR 429/4885PSMD14 3539/4885HSD11B1 220/4885 |
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | TSHR 3520/4885PSMD14 2307/4885HSD11B1 2061/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | TSHR 3570/4885PSMD14 2425/4885HSD11B1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.